Glucocerebrosidase (Gcase) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glucocerebrosidase (GCase) is a lysosomal enzyme encoded by the GBA1 gene that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide[1]. GCase activity in blood and CSF is an emerging biomarker for Parkinson's disease (PD) and Lewy body dementia (DLB), particularly in carriers of GBA1 mutations[2].
Loss of GCase function leads to Gaucher disease, and heterozygous GBA1 mutations are the most common genetic risk factor for PD, increasing risk by 5-20 fold depending on mutation severity[3].
| Property | Value |
|---|---|
| Full Name | Glucocerebrosidase |
| Abbreviation | GCase |
| Gene Symbol | GBA1 |
| UniProt ID | P04062 |
| Molecular Weight | ~63 kDa (dimer) |
| Subcellular Location | Lysosome |
| Sample Types | Plasma, Serum, CSF, Dried Blood Spot |
| Detection Method | Enzyme activity assay, Mass Spectrometry |
GCase serves as both an enzyme activity marker and a genetic risk indicator in neurodegeneration:
| Population | GCase Activity | Change |
|---|---|---|
| Healthy controls | 100% (baseline) | Reference |
| PD (non-carriers) | 70-85% | Reduced |
| PD (GBA1 carriers) | 40-60% | Significantly reduced |
| DLB | 65-80% | Reduced |
| Gaucher disease (heterozygote) | 35-50% | Severely reduced |
GCase activity is a diagnostic and progression biomarker for PD[4]:
In DLB, GCase indicates alpha-synuclein pathology[5]:
| Factor | Recommendation |
|---|---|
| Collection | EDTA plasma or serum; dried blood spots acceptable |
| Fasting | Overnight fast preferred (reduces lipid interference) |
| Centrifugation | Within 2 hours of collection |
| Storage | -80°C for long-term; avoid repeated freeze-thaw |
| Assay | Use standardized fluorescent substrate (luciferin) |
GCase is essential for glycosphingolipid metabolism[6]:
The relationship between GBA1 and PD involves several mechanisms:
| Therapeutic Approach | Mechanism | Status |
|---|---|---|
| Enzyme replacement | Recombinant GCase delivery | Under investigation |
| Small molecule chaperones | Ambroxol, migalastat stabilize GCase | Clinical trials |
| Substrate reduction | Eliglustat reduces glucosylceramide | Approved for Gaucher |
| Gene therapy | AAV-GBA1 delivery | Preclinical |
| ASO therapy | Modulate GBA1 expression | Preclinical |
Ambroxol is a GCase chaperone being repurposed for PD[7]:
The study of Glucocerebrosidase (Gcase) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Beauchamp MH, et al. (2015). Gaucher disease: Pathogenesis and clinical manifestations. Handb Clin Neurol. 130:101-125. PMID:26003242 ↩︎
Alcalay RN, et al. (2014). Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 138(Pt 9):2648-2658. PMID:25008109 ↩︎
Sidransky E, et al. (2009). Multicenter analysis of glucocereposidase mutations in Parkinson disease. N Engl J Med. 361(17):1651-1661. PMID:19846850 ↩︎
Liu G, et al. (2022). GCase activity as a biomarker in Parkinson's disease. Mov Disord. 37(1):82-92. PMID:34750897 ↩︎
Giraldo ME, et al. (2018). Glucocerebrosidase activity in dementia with Lewy bodies. Neurobiol Aging. 62:45-52. PMID:29127847 ↩︎
Mazzulli JR, et al. (2011). Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 146(1):37-52. PMID:21700325 ↩︎
Narayan M, et al. (2021). Ambroxol for the treatment of Parkinson's disease: A review. J Parkinsons Dis. 11(4):1577-1588. PMID:34366378 ↩︎